Skin reactions during pediatric cancer treatment can be painful, stigmatizing, and sometimes threaten a child’s ability to stay on therapy. In this episode of PeDRA Pearls, Dr. Christina Boull and Dr. Rebecca Levy discuss PeDRA's Skin Tumors and Reactions to Cancer Therapies (STARC) Focused Study Group and its work to prevent, recognize, and manage these toxicities. They highlight multicenter efforts spanning photosensitivity prevention, survivorship outcomes, and targeted therapy side effects—including MEK inhibitor–associated mucocutaneous toxicities—plus the need for stronger derm–onc collaboration, better trial reporting, and evidence-based consensus guidelines.Click here for more information.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from PeDRA Pearls
PeDRA's at SID - Reflections from Dr. Lawrence Eichenfield
PeDRA's at SID - Reflections with Dr. Jinia El-Feghaly
PeDRA's at SID - Reflections on the EDD Symposium with Keith Choate, MD, PhD
PeDRA's at SID - Kick Off Interview with Mike Siegel, PhD
Get summaries like this every morning.
Free AI-powered recaps of PeDRA Pearls and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.